The 5 analysts offering 12-month price forecasts for Cue Biopharma Inc have a median target of 30.00, with a high estimate of 32.00 and a low estimate of 28.00. The median estimate represents a +132.74% increase from the last price of 12.89.
The current consensus among 5 polled investment analysts is to Buy stock in Cue Biopharma Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.39
Reporting Date Nov 26
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.